Lenvatinib and pembrolizumab in the treatment of metastatic endometrial cancer: literature review and case report
In 2019 in Russia endometrial carcinoma was diagnosed in 27151 patients, 6820 women died from the disease. The standard of frontline therapy for patients with advanced endometrial carcinoma is platinum and taxane-based chemotherapy with satisfactory efficacy – the median progression-free survival is...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2021-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/6589 |
| _version_ | 1797842026325082112 |
|---|---|
| author | A. A. Rumyantsev |
| author_facet | A. A. Rumyantsev |
| author_sort | A. A. Rumyantsev |
| collection | DOAJ |
| description | In 2019 in Russia endometrial carcinoma was diagnosed in 27151 patients, 6820 women died from the disease. The standard of frontline therapy for patients with advanced endometrial carcinoma is platinum and taxane-based chemotherapy with satisfactory efficacy – the median progression-free survival is about 13 months, and up to 50% of patients achieve objective response to therapy. On the other hand, for patients with recurrent endometrial cancer after frontline chemotherapy the results of chemotherapy remained generally unsatisfactory, the objective response rate to standard treatment was about 10 to 15%. During the last few years there significant progress has been made in this area – studies identified a subgroup of patients with a high level of microsatellite instability (MSI-high) highly sensitive to pembrolizumab therapy. In this subset of patients, who account for up to 25% of patients with metastatic endometrial cancer, the objective response rate to pembrolizumab monotherapy is up to 57%. Further studies have shown that the addition of lenvatinib to pembrolizumab therapy may be a highly effective therapeutic option for patients without MSI-high. This article describes a clinical case of the successful therapy of a patient with platinumresistant endometrial carcinoma with a combination of pembrolizumab and lenvatinib. |
| first_indexed | 2024-04-09T16:41:14Z |
| format | Article |
| id | doaj.art-3cd397fcb7ea4a27bae01e43cc330000 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:41:14Z |
| publishDate | 2021-12-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-3cd397fcb7ea4a27bae01e43cc3300002023-04-23T06:56:41ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902021-12-0102012412810.21518/2079-701X-2021-20-124-1285950Lenvatinib and pembrolizumab in the treatment of metastatic endometrial cancer: literature review and case reportA. A. Rumyantsev0Blokhin National Medical Research Center of OncologyIn 2019 in Russia endometrial carcinoma was diagnosed in 27151 patients, 6820 women died from the disease. The standard of frontline therapy for patients with advanced endometrial carcinoma is platinum and taxane-based chemotherapy with satisfactory efficacy – the median progression-free survival is about 13 months, and up to 50% of patients achieve objective response to therapy. On the other hand, for patients with recurrent endometrial cancer after frontline chemotherapy the results of chemotherapy remained generally unsatisfactory, the objective response rate to standard treatment was about 10 to 15%. During the last few years there significant progress has been made in this area – studies identified a subgroup of patients with a high level of microsatellite instability (MSI-high) highly sensitive to pembrolizumab therapy. In this subset of patients, who account for up to 25% of patients with metastatic endometrial cancer, the objective response rate to pembrolizumab monotherapy is up to 57%. Further studies have shown that the addition of lenvatinib to pembrolizumab therapy may be a highly effective therapeutic option for patients without MSI-high. This article describes a clinical case of the successful therapy of a patient with platinumresistant endometrial carcinoma with a combination of pembrolizumab and lenvatinib.https://www.med-sovet.pro/jour/article/view/6589uterine carcinomaendometrial cancerpembrolizumablenvatinibtargeted therapyimmunotherapymicrosatellite instabilitymsi |
| spellingShingle | A. A. Rumyantsev Lenvatinib and pembrolizumab in the treatment of metastatic endometrial cancer: literature review and case report Медицинский совет uterine carcinoma endometrial cancer pembrolizumab lenvatinib targeted therapy immunotherapy microsatellite instability msi |
| title | Lenvatinib and pembrolizumab in the treatment of metastatic endometrial cancer: literature review and case report |
| title_full | Lenvatinib and pembrolizumab in the treatment of metastatic endometrial cancer: literature review and case report |
| title_fullStr | Lenvatinib and pembrolizumab in the treatment of metastatic endometrial cancer: literature review and case report |
| title_full_unstemmed | Lenvatinib and pembrolizumab in the treatment of metastatic endometrial cancer: literature review and case report |
| title_short | Lenvatinib and pembrolizumab in the treatment of metastatic endometrial cancer: literature review and case report |
| title_sort | lenvatinib and pembrolizumab in the treatment of metastatic endometrial cancer literature review and case report |
| topic | uterine carcinoma endometrial cancer pembrolizumab lenvatinib targeted therapy immunotherapy microsatellite instability msi |
| url | https://www.med-sovet.pro/jour/article/view/6589 |
| work_keys_str_mv | AT aarumyantsev lenvatinibandpembrolizumabinthetreatmentofmetastaticendometrialcancerliteraturereviewandcasereport |